← Eichor
Condition: Malignant Histiocytosis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Malignant Histiocytosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Phase 1 · 6 location(s) · LTZ Therapeutics, Inc. · NCT07121946Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
Phase N/A · 1 location(s) · Ain Shams University · NCT07057765Histiocytic Disorder Follow-up Study
Phase N/A · 1 location(s) · University of Alabama at Birmingham · NCT05915208A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06736613Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy
Phase N/A · 1 location(s) · Incyte Biosciences Italy S.r.l · NCT06299553DALY II Japan/MB-CART2019.1 for DLBCL
Phase 2 · 5 location(s) · Miltenyi Biomedicine GmbH · NCT07288879Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
Phase 2 · 1 location(s) · Zhejiang Provincial People's Hospital · NCT06534762Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06151080Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL
Phase 2 · 7 location(s) · University Medical Center Groningen · NCT05641428International Rare Histiocytic Disorders Registry (IRHDR)
Phase N/A · 15 location(s) · The Hospital for Sick Children · NCT02285582DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cance
Phase 2/Phase 3 · 16 location(s) · Cancer Research UK · NCT05768178Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT06980116CAR-T Followed by Bispecific Antibodies
Phase 2 · 2 location(s) · Abramson Cancer Center at Penn Medicine · NCT04889716Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Phase 1 · 1 location(s) · Florida International University · NCT05857969Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06891157Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Phase 2 · 12 location(s) · Carl Allen · NCT04079179Real-World Study of DLBCL With Different Genetic Subtypes
Phase N/A · 1 location(s) · Ruijin Hospital · NCT06026488Glofitamab in Chinese Patients With R/R DLBCL
Phase N/A · 1 location(s) · Peking Union Medical College Hospital · NCT06481826Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
Phase N/A · 5 location(s) · Pell Bio-Med Technology Co., Ltd. · NCT05377307Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
Phase N/A · 1 location(s) · Paul Szabolcs · NCT04528355Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Phase 2 · 1 location(s) · Virginia Commonwealth University · NCT06846463A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / R
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07548697Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relap
Phase 2 · 1 location(s) · Australasian Leukaemia and Lymphoma Group · NCT06287398Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
NA · 2 location(s) · Memorial Sloan Kettering Cancer Center · NCT05940272Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta
Phase 1 · 1 location(s) · University Health Network, Toronto · NCT05950802Project: Every Child for Younger Patients With Cancer
Phase N/A · 278 location(s) · Children's Oncology Group · NCT02402244Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
Phase 1 · 1 location(s) · Shanghai Exuma Biotechnology Ltd. · NCT06830031Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)
Phase N/A · 1 location(s) · University Medical Center Goettingen · NCT06526065Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07255963
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.